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A comparison of recombinant thrombin to bovine
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Objectives:Recombinant thrombin (rThrombin) is a potential hemostatic alternative to bovine and human plasma-derived
thrombin. This report examines the clinical results for the vascular surgery subgroup of patients enrolled in a larger
double-blind, randomized, multicenter trial, which evaluated the comparative safety and efficacy of rThrombin and
bovine plasma-derived thrombin (bThrombin) when used as adjuncts to surgical hemostasis.
Methods: Data from the 164 vascular patients who underwent either a peripheral arterial bypass (PAB) or arteriovenous
graft (AV) procedure are included in this analysis. Time to hemostasis at proximal and distal anastomotic sites at 1.5-, 3-,
6-, and 10-minute intervals was determined by procedure (PAB or AV) and overall (PAB  AV). Baseline and day 29
immunologic sera were analyzed. The incidences of postoperative adverse events were compared between treatment
groups. Categorical adverse events were evaluated in relation to thrombin product antibody formation.
Results: Patients were randomized to either bThrombin (n  82) or rThrombin (n  82). Procedures included PAB
(n  88) and AV (n  76). The bThrombin and rThrombin groups were well matched for demographics and baseline
characteristics. A comparable incidence of anastomotic hemostasis was observed in both treatment groups at 10 minutes
(94% bThrombin, 91% rThrombin). The incidence of hemostasis was lower at all time points for PAB procedures
compared with AV procedures. In the PAB group, a significantly greater proportion of patients receiving rThrombin
(55%) achieved hemostasis at 3 minutes compared with bThrombin (39%; P< .05). Adverse event profiles and laboratory
findings were similar between groups. No patients in the rThrombin group developed anti-rThrombin product
antibodies at day 29, whereas 27% of patients in the bThrombin group developed antibodies to bThrombin product
(P < .0001).
Conclusions: rThrombin or bThrombin used as a hemostatic ancillary for anastomotic bleeding was equally effective at 10
minutes; however, rThrombin compared with bThrombin may provide a more rapid onset of hemostasis at 3 minutes in
PAB procedures. Adverse events were similar between the two thrombins. In patients undergoing vascular surgery, both
treatments were similarly well tolerated, although rThrombin demonstrated a superior immunogenicity profile. ( J Vasc
Surg 2008;47:1266-73.)Topically applied thrombin is frequently used in recon-
structive vascular and vascular access procedures. In the
United States, an estimated $250million are spent annually
on the use of topical thrombin in over 1 million surgical
procedures.1 Currently available sources of thrombin used
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1266in surgical procedures include bovine and human pooled
plasma-derived thrombin. Though some clinical trials of
bovine thrombin as a component of fibrin sealants and
other combination products have been reported, the he-
mostatic efficacy of bovine thrombin (bThrombin) alone
has not been extensively studied in prospective, random-
ized comparative studies. Nevertheless, bThrombin has
gained widespread acceptance as an adjunct to achieving
hemostasis in many types of surgical procedures, includ-
ing vascular, orthopedic, and skin graft procedures. How-
ever, bThrombin has been associated with anaphylaxis
and the development of antibodies which can cross react
with human factor V or human thrombin, sometimes
leading to life-threatening coagulopathy and consider-
able morbidity.1-10 Human pooled plasma-derived throm-
bin has recently become commercially available as a stand-
alone topical hemostat; this product carries the risk of viral
transmission, and the degree of safety conferred by the best
processing techniques must be continuously evaluated.11
Recombinant thrombin (rThrombin) is a potential al-
ternative to plasma-derived thrombins. Theoretically, a re-
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protein that is safe and effective, but without the attendant
concerns of antibody production or viral transmission. To
investigate this hypothesis, rThrombin (ZymoGenetics, Se-
attle, Wash) was compared with bThrombin (Thrombin-
JMI, GenTrac, Inc, Middleton, Wis) in a recently com-
pleted phase 3, prospective, double-blind, randomized
trial. That trial included patients undergoing vascular, liver,
and spine procedures, and the overall results were recently
published.12
In contrast to most patients undergoing spine and liver
procedures, obstacles to hemostasis such as uremia, chronic
renal dialysis, concomitant antiplatelet/anticoagulantmedica-
tions, vasculopathy, and hypertension are common in the
vascular patient population. In addition, patients with vas-
cular disease or in need of vascular access often undergo
multiple vascular procedures which may increase thrombin
exposure and potentiate an immunologic response to
thrombin-based product. It was with the unique aspects of
the vascular patient population inmind that a more detailed
analysis of the phase 3 vascular cohort was performed. This
report details the results of this analysis and characterizes
the relative safety and efficacy of topical rThrombin and
bThrombin as a hemostatic ancillary in patients undergoing
peripheral arterial bypass and arteriovenous graft proce-
dures.
METHODS
A detailed comparative analysis was performed on the
vascular cohort of patients from a larger double-blind,
randomized, prospective trial conducted at 34 centers in
the United States. Exploratory statistical analyses not spec-
ified a priori were conducted to evaluate the safety and
efficacy of bThrombin (Thrombin-JMI) versus rThrombin
in a subset of patients undergoing vascular surgery. Sixteen
centers participating in the prospective trial enrolled pa-
tients undergoing peripheral artery bypass (PAB) or arte-
riovenous (AV) graft formation procedures.
Details regarding the design of the prospective trial
have been reported previously.12 Eligible patients under-
going PAB or AV graft procedures with a polytetrafluoro-
ethylene (PTFE) graft or revision procedures with PTFE
graft-graft anastomoses were randomized in a 1:1 ratio
prior to surgery to receive either bThrombin (1000
U/mL) or rThrombin (1000 U/mL). Dynamic allocation
was used (real-time, computerized method) to attain an
approximately equal number of patients randomized to
rThrombin and bThrombin by surgeon and within each
surgery type. Surgeons were blinded to treatment assign-
ment and study drug was delivered to the operating room
from the pharmacy as a clear, colorless solution in identical
syringes. The study drugs were applied topically to anasto-
motic bleeding site(s) in combination with an absorbable
gelatin sponge (Surgifoam, Johnson & Johnson Wound
Management, Somerville, NJ). Time to hemostasis (TTH),
summarized as the incidence of hemostasis within 10minutes,
was determined for four prespecified anastomotic sites: PAB
proximal anastomosis, PAB distal anastomosis, AV arterialanastomosis, and AV venous anastomosis. Administration of
coagulation impeding medications was recorded.
Adverse events and clinical laboratory abnormalities
were recorded up to day 29 (5 days). Adverse events of
potential clinical interest were prospectively categorized as
hemorrhagic, cardiac, hypersensitivity, or thromboembolic
based upon clinical importance (cardiac) or whether they
were known or possible complications from administration
of topical thrombin; a listing of events included in each
category is shown in Table I. Adverse events were coded
according to the Medical Dictionary for Regulatory Activ-
ities (MedDRA) version 9. Standard clinical laboratory data
and prothrombin time (PT), activated partial thromboplas-
tin time (aPTT), and international normalized ratio (INR)
were measured, and perioperative transfusion was recorded
as a surrogate marker for blood loss. Antibodies to either
bThrombin or rThrombin product were evaluated in
plasma samples collected at baseline and at day 29 (5
days) using assays developed by ZymoGenetics, Inc (Seat-
tle, Wash).
The differences in the incidence of hemostasis between
treatment groups at the timepoints of 1.5, 3, 6, and 10
minutes were evaluated using generalized estimating equa-
tions (GEE) to account for potential correlation between
measurements from the same patient. Fisher exact test was
used to compare the incidence of antiproduct antibodies
between treatment groups, and exact binomial confidence
intervals were created for an analysis of the potential relation-
ship between adverse clinical outcomes and the presence of
antiproduct antibodies after treatment with study drug.
RESULTS
A total of 183 vascular patients were enrolled and
randomized between October 2005 and July 2006; 19
patients were not treated with study drug due to lack of an
appropriate TTH evaluation site or other reasons (Fig).
One hundred sixty-four patients received blinded study
drug (bThrombin, n  82; rThrombin, n  82), and 161
completed the study. Eighty-eight and 76 patients under-
went PAB and AV graft procedures, respectively, and were
randomized and treated. The majority of patients (90%
bThrombin, 85% rThrombin) were treated with blinded
study drug at more than one anastomotic site. Fifty-eight
percent were male, and the median age was 64 years.
Baseline demographics, baseline characteristics, and type of
surgical procedure performed were similar between treat-
ment groups (Table II). Overall, the use of anticoagulants/
antiplatelet medications was similar between treatment
groups (66% bThrombin, 62% rThrombin). Patients un-
dergoing PAB (89% bThrombin, 84% rThrombin) more
often received preoperative coagulation-impeding medica-
tions than patients undergoing AV graft procedures (39%
bThrombin, 37% rThrombin).
The incidence of hemostasis within 10 minutes at all
hemostasis evaluation sites (PAB  AV graft) was compa-
rable between groups (94% bThrombin, 91% rThrombin)
(Table III). In patients undergoing PAB surgery, the over-
all incidence of hemostasis within 10minutes was 88% (90%
gic gr
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graft surgery, the overall incidence of hemostasis within 10
minutes was 97% (99% bThrombin, 96% rThrombin) (Ta-
Fig. Patient disposition.
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Table II. Demographic and baseline characteristics
Characteristic
bThrombin
(N  82)
rThrombin
(N  82)
Median age, y (range) 63.5 (30, 85) 65.0 (28, 88)
Gender, n (%)
Female 34 (41) 35 (43)
Male 48 (59) 47 (57)
Surgery, n (%)
PAB – total 44 (54) 44 (54)
Proximal and distal 39 (89) 38 (86)
Proximal only 3 (7) 2 (5)
Distal only 2 (5) 4 (9)
AV graft – total 38 (46) 38 (46)
Arterial and venous 35 (92) 32 (84)
Arterial only 2 (5) 3 (8)
Venous only 1 (3) 3 (8)
Preoperative coagulation
impeding medications 54 (66) 51 (62)
Comorbidity, n (%)
Hypertension 73 (89) 70 (85)
Heart failure 16 (20) 15 (18)
Coronary artery disease 28 (34) 33 (40)
COPD/pulmonary 17 (21) 17 (21)
Diabetes 42 (51) 42 (51)
Renal insufficiency 41 (50) 42 (51)
PAB, Peripheral artery bypass; AV, arteriovenous; COPD, chronic obstruc-
tive pulmonary disease.egor
osis
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ialstatistically significantly greater incidence of hemostasis was
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rThrombin, 39% bThrombin, P .05) in PAB procedures.
Of the primary hemostasis evaluation sites (proximal
anastomoses), 14 sites (7 bThrombin, 7 rThrombin) failed
to achieve hemostasis within 10 minutes. Blinded study
drug was the most frequently administered treatment fol-
lowing hemostatic failure, and was successful in achieving
Table III. Cumulative incidence of hemostasis over time
by treatment group at all (PAB  AV graft) anastomotic
sites
bThrombin
(82 patients)
rThrombin
(82 patients) P value
Number of bleeding sites 156 152
Time to hemostasis, n
(%) within:
1.5 min 56 (36) 62 (41) 0.44
3 min 90 (58) 103 (68) 0.11
6 min 124 (79) 128 (84) 0.33
10 min 147 (94) 138 (91) 0.28
PAB, Peripheral artery bypass; AV, arteriovenous.
Bleeding sites: PAB, proximal and distal; AV, arterial and venous.
General Estimating Equation analysis for nonindependent variables.
Table IV. Cumulative incidence of hemostasis over time
by treatment group at AV graft anastomotic sites
bThrombin
(82 patients)
rThrombin
(82 patients) P value
Number of bleeding sites/
number of patients 73/38 70/38
Time to hemostasis, n (%)
within:
1.5 min 39 (53) 42 (60) 0.49
3 min 58 (79) 58 (83) 0.66
6 min 68 (93) 66 (94) 0.77
10 min 72 (99) 67 (96) 0.29
AV, Arteriovenous.
Bleeding sites: AV, arterial and venous.
General Estimating Equation analysis for nonindependent variables.
Table V. Cumulative incidence of hemostasis over time
by treatment group at PAB anastomotic sites
bThrombin
(82 patients)
rThrombin
(82 patients) P value
Number of bleeding sites/
number of patients 83/44 82/44
Time to hemostasis, n (%)
within:
1.5 min 17 (20) 20 (24) 0.58
3 min 32 (39) 45 (55) 0.046
6 min 56 (67) 62 (76) 0.28
10 min 75 (90) 71 (87) 0.47
PAB, Peripheral artery bypass.
Bleeding sites: PAB, proximal and distal.
General estimating equation analysis for nonindependent variables.hemostasis at all but one site in a patient receiving rThrom-bin. There were no clinically meaningful differences in the
rate of perioperative transfusion between treatment groups
(data not shown). There were no cross-over thrombin
applications between treatment groups and no potentially
confounding thrombin product administration during the
29-day study period.
No deaths occurred during the study in either group.
Six patients in the bThrombin group experienced graft
complications or thrombosis (two PAB, four AV) while
seven patients in the rThrombin group developed graft
occlusion (two PAB, five AV). Serious adverse events oc-
curred in 22% of those receiving bThrombin vs 17% in
those receiving rThrombin. Serious adverse events were
evenly distributed among organ system class and were
consistent with underlying subject comorbidities and
known surgical complications. Prospectively categorized
adverse events (hemorrhagic, cardiac, hypersensitivity, and
thromboembolic) are listed by treatment group in Table
VI. The incidence of adverse events within these categories
was similar between treatment groups. Peri- and postoper-
ative bleeding complications were experienced by approxi-
mately 20% of patients in both treatment groups, and
thromboembolic complications occurred in 9% of patients
in each group. No postoperative cardiac events were attrib-
uted to study drug in either treatment group. Nomeaning-
ful differences were found between treatment groups at
baseline or day 29 for clinical laboratory results, PT, aPTT,
or INR.
A total of 161 patients were evaluated for the presence
of antibodies to either the bThrombin or the rThrombin
products at baseline and postexposure (Table VII). Anti-
Table VI. Incidence of adverse events of potential
clinical interest by category and treatment groupa
bThrombin
N  82
rThrombin
N  82
Hemorrhagic, n (%) 17 (21) 16 (20)
Cardiac, n (%) 11 (13) 12 (15)
Hypersensitivity, n (%) 9 (11) 9 (11)
Thromboembolic, n (%) 7 (9) 7 (9)
aCategories grouped by MedDRA coded events; thromboembolic category
includes thrombotic and embolic adverse events.
Table VII. Development of anti-product antibodies
bThrombin rThrombin P value
Detectable at baseline 6/81 (7.4%) 3/80 (3.8%)
Antibody positivea 22/81 (27%) 0/80 (0.0) .0001
Seroconversionb 17/75 (23%) 0 (0.0)
1.0 titer unit changec 5/6 (83%) 0 (0.0)
aSeroconversion or 1 unit increase in titer postbaseline.
bDenominators include only patients who had a postbaseline observation
and no detectable anti-product antibodies at baseline.
cDenominators include only patients who had a postbaseline observation
and had detectable anti-product antibodies at baseline.product antibodies were detectable at baseline in six pa-
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treatment group, three patients (3.8%) had anti-rThrombin
antibodies at baseline. At day 29, 27% of patients in the
bThrombin group had seroconverted or had a 10-fold
increase in detectable antibodies to bThrombin product.
No patients receiving rThrombin seroconverted or had an
increase in anti-rThrombin product antibody titer. This
difference in immunogenicity was highly statistically signif-
icant (P  .0001). In the bThrombin group, antibody
positivity due to seroconversion occurred in 17 patients and
an increase in anti-bThrombin product antibody 1 titer
unit occurred in five of the six patients with bThrombin
antibodies at baseline.
Because of the reported association between antibodies
to bThrombin and adverse events, selected adverse clinical
outcomes were sorted by presence or absence of postexpo-
sure antibodies to bThrombin product (Table VIII). Al-
though patients who developed antibodies to bThrombin
product had a numerically increased incidence of hypersen-
sitivity events compared with antibody-negative patients
(23% vs 7%) and an elevation in aPTT relative to patients
without bThrombin antibodies (36% vs 20%), these differ-
ences were not statistically significant.
DISCUSSION
Thrombin is a central component in the coagulation
cascade. Thrombin activates platelets and cleaves fibrino-
gen to fibrin, leading directly to clot formation. Thrombin
also activates factor XIII, leading to fibrin cross-linking and
clot stability.13 The ability of thrombin to bypass the initial
enzymatic steps of the coagulation pathway has led to a
widespread adoption of thrombin from multiple biologic
sources as a topical hemostatic agent. Thrombin is rapidly
neutralized by naturally circulating plasma inhibitors, in-
cluding anti-thrombin III, alpha-2-macroglobulin, and
heparin cofactor II, which act to limit its duration of action
and prevent the active form from diffusing into the general
Table VIII. Association of postexposure
anti-bThrombin product antibodies with adverse
clinical outcomes
Anti-bThrombin product
antibody
Negative n/N
(%) 95% CI
Positive n/N
(%) 95% CI
Patients with thromboembolic
events
6/59 (10) 1/22 (5)
4%-21% 0%-23%
Patients with hypersensitivity
events
4/59 (7) 5/22 (23)
2%-16% 8%-45%
Patients with elevated aPTTa 12/59 (20) 8/22 (36)
11%-33% 17%-59%
Patients with hemorrhagic events 14/59 (24) 3/22 (14)
14%-37% 3%-35%
Patients with cardiac events 8/59 (14) 3/22 (14)
6%-25% 3%-35%
aPTT, Activated partial thromboplastin time.
aaPTT elevation as any value greater than upper.circulation.14-17Hemostasis is vital to the success of any vascular proce-
dure. When ligation, electrocautery, or simple pressure fails
to arrest bleeding, surgeons turn to a number of hemostatic
aids. Mechanical hemostats include relatively inert com-
pounds such collagen gelatins (Surgifoam) and cellulose
(Surgicel, Johnson & JohnsonWoundManagement, Som-
erville, NJ), which serve as a lattice for clot formation. To
accelerate this process, exogenous thrombin has been
added by surgeons to these “carrier” products. The effec-
tiveness of this combination therapy has lead to the in-
creased use of topical thrombins derived from either bovine
or human plasma sources.
Human pooled plasma-derived thrombin, a product
collected from up to 60,000 plasma donors per manufac-
turing lot, is now commercially available as a stand-alone
product and used in combination with hemostatic and
fibrin sealant products. The main risks associated with
human plasma-derived thrombin include possible transmis-
sion of blood-borne pathogens such as retrovirus, viral
hepatitis, and parvovirus as well as prions.11 Concerns
regarding the transmission of blood-borne pathogens by
human pooled plasma-derived thrombin have been largely
reduced but not eliminated by improved processing. These
improvements led to approval as a fibrin/hemostatic com-
ponent.2
Bovine plasma-derived thrombin (Thrombin-JMI) is
one of the most commonly used topical surgical hemostats
in the United States market. Though used in over 1 million
surgical cases per year, with an average of 10,000 IU per
procedure, there is growing recognition that antibodies to
bovine thrombin and bovine factor V can develop from the
innate human immune response to the -Gal glycosylation
moiety unique to lower mammalian species as well as other
antigenic impurities in the product.1 These antibodies can,
by cross-reacting with endogenous human coagulation fac-
tors and acting as acquired inhibitors of native human
thrombin and factor V, cause a variety of complications
ranging from laboratory abnormalities to potentially life-
threatening bleeding or thrombotic complications. By
1996, clinical reports of immune-mediated events prompted
the FDA to impose a black box warning on all bovine
thrombin products, warning specifically against re-exposure
to bovine thrombin. Since that specific warning, numerous
cases of antibody-related complications from diverse surgi-
cal settings continue to be reported, suggesting that pa-
tients and their doctors have little awareness regarding the
potential risks associated with exposure to xenogeneic
thrombin.12,18-29 Further, clinicians cannot easily elucidate
the potential relationship between anti-bovine thrombin
antibodies and bleeding events due to the lack of a com-
mercially available antibody assay.
The potential and documented adverse conse-
quences associated with bovine and human plasma-
derived thrombin strongly influenced the development
of rThrombin.19-22,30,31 Preclinical trials demonstrated
topical rThrombin to be safe in animals.32 A phase 2 trial
demonstrated that rThrombin was well tolerated and min-
imally immunogenic and enabled the pivotal phase 3 trial
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bin versus bThrombin. This study, in 411 patients in four
surgical settings (PAB, AV graft formation, liver, and
spine), was recently completed and published.12 Recombi-
nant thrombin was found to be safe and as efficacious as
bThrombin. Antibodies developed postexposure in 43 of
200 patients (21.5%) exposed to bThrombin, whereas non-
neutralizing antibodies to rThrombin product were de-
tected in 3 of 198 patients (1.5%; P  .0001) receiving
rThrombin.
This report concerns the subgroup of vascular patients
in the phase 3 trial. The use of topical thrombin in vascular
patients differs from its use in spine and liver patients in that
thrombin is used in vascular surgery as an ancillary for
hemostasis at small, high pressure anastomotic arterial
bleeding sites. Furthermore, patients undergoing recon-
structive vascular procedures differ from other surgical
populations due to the presence of reoperative scar, vascu-
lopathy, and use of concomitant anticoagulants/antiplate-
let agents. Presumably as a result of these factors alone and
in combination, a numerical difference was observed in the
incidence of hemostasis at 10 minutes for spine, liver, and
AV procedures compared with PAB procedures. The po-
tential statistical significance of this difference was not
evaluated. Of the sites that failed to achieve hemostasis at
10 minutes, over two-thirds were PAB procedure sites.12 It
was this numerical trend that stimulated additional sub-
group analyses in order to further examine the time to
hemostasis in vascular patients.
In further analyses, the incidence of hemostasis at the
time points of 1.5, 3, 6, and 10 minutes was numerically
superior for the AV procedures compared with PAB proce-
dures at all time points. The most likely explanation for this
differential is the greater use of coagulation-impedingmed-
ications in the PAB group. The incidence of hemostasis in
PAB procedures at 3 minutes was significantly higher with
rThrombin than with bThrombin when analyzed by pro-
cedure and treatment group. At 6 minutes, this difference
in hemostasis narrowed but still numerically favored
rThrombin. At 10 minutes, the two groups were numeri-
cally equivalent. The reasons for this observation are not
clear. This effect may not be clinically evident in surgical
settings where the coagulation system is normal and not
pharmacologically compromised, but in vascular recon-
structive procedures this is rarely the case. Whether these
differences in topical thrombin performance exist as chance
observations or are the result of differences in biochemical
properties cannot be determined by this study. Clarification
awaits future studies of rThrombin application in patients
undergoing reconstructive vascular procedures.
Although much has been documented regarding safety
concerns associated with bThrombin, no obvious differ-
ences in safety were seen in vascular patients treated with
bThrombin compared with those in the rThrombin treat-
ment group. Incidence of graft occlusion and hemorrhagic,
thromboembolic, hypersensitivity, and cardiac events was
similar between groups and not dissimilar from that ex-
pected in this patient population. Laboratory abnormali-ties, and in particular changes in coagulation parameters,
were comparable between treatment groups.
Baseline antibodies to study drug were observed in
both treatment groups. This finding is not uncommon
among recombinant biotherapeutics. For example, evi-
dence of preexisting antibodies has been observed for re-
combinant human interferons and interleukins.33-36 The
presence of anti-bThrombin product antibodies in this
population is presumably related to prior exposure to bo-
vine thrombin during previous surgical procedures. The
nature and significance of this finding is unknown.
When patients with anti-bThrombin product antibod-
ies postexposure were compared with those without anti-
bodies, a numerically increased incidence of hypersensitiv-
ity reactions and elevation in aPTT was observed. Because
antibodies formed in response to bThrombin exposure can
be pathogenic, it was both timely and appropriate to com-
pare the adverse clinical outcomes in patients who did and
did not form antibodies to the bThrombin product. Not
surprisingly, the small number of events and sample size of
the current study preclude an unambiguous interpretation
of this potential relationship.
One final noteworthy observation in this study is the
prevalence of bThrombin antibodies in the vascular patient
population compared with the nonvascular cohort of the
overall study (spine and liver). Patients undergoing PAB
and AV graft procedures had a baseline incidence of anti-
bodies to bThrombin product of 7.4%, nearly twice that of
measured antibodies to the rThrombin product. In con-
trast, the incidence of antibodies to bThrombin product in
the spine and liver cohorts at baseline in the overall study
was only 3.4% (unpublished data), less than half that in the
vascular group. Unlike patients undergoing spine and liver
surgery, patients with peripheral arterial disease and in need
of AV vascular access frequently undergo multiple and redo
vascular procedures where repeat potential bThrombin ex-
posure is common. This unique aspect of the vascular
surgery patient population is important, since following
exposure to bThrombin, 27% of patients either serocon-
verted or increased their titer of antibodies to the bThrom-
bin product. This translates to approximately one in four
patients developing antibodies to bThrombin postopera-
tively, placing them at risk for known adverse events due to
bThrombin-induced antibodies. This is consistent with
previous reports of the immunogenicity of bThrombin in
other surgical populations.27,37,38
There are certain caveats to the above observations.
Since this study was not designed to detect specific statisti-
cal differences in the vascular subgroup of patients, statisti-
cal findings should be interpreted cautiously. It is certainly
possible that the increased incidence of hemostasis at 3
minutes in the PAB group treated with rThrombin was
observed by chance alone. Likewise, the potential correla-
tion of the hypersensitivity adverse events and elevation in
aPTT with anti-bThrombin product antibodies is an inter-
esting observation, but a larger study specifically addressing
this finding will be required to confirm or refute this
observation.
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rThrombin treatment in a subgroup of patients undergoing
PAB and AV graft surgery provides a number of observa-
tions and raises interesting questions. First, rThrombin
resulted in comparable hemostatic efficacy relative to
bThrombin in vascular surgery patients, and demonstrated
an increased incidence of hemostasis at 3 minutes in pa-
tients undergoing PAB surgery; whether this is a reproduc-
ible or clinically meaningful finding remains to be deter-
mined in additional studies. Clearly, both thrombins have
significant activity in the first minutes after application in a
surgical setting marked by anticoagulation and pathologic
platelet dysfunction. Second, the rThrombin safety profile,
as characterized by adverse events and laboratory evalua-
tions, is similar to that of bThrombin, although certain
adverse events were numerically more common in patients
with anti-bThrombin product antibodies. Further, rThrom-
bin does not evoke a significant immunogenic response, in
contrast to bThrombin. Although there are numerous pub-
lished case reports in the medical literature, clinicians may
benefit from a well-controlled trial designed to detect and
characterize the spectrum of adverse consequences to
bThrombin product exposure.
The authors thank Linda Zuckerman, PhD, an em-
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Inc., for providing statistical expertise.
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